[citation needed] This pathogen may latently infect the chorionic villi tissues of pregnant women, thereby impacting pregnancy outcome.

The morphology is quite variable and seems to depend, in part, on the age of the culture as the smallest form observed, coming from the elementary body, is 80nm to 100nm wide in diameter.

These cells can contain different structures such as ribosome-like granules, nuclear areas of netlike strands, dense cytoplasmic bodies and large vacuoles.

[16] Culturing it is demanding and time-consuming due to specialized requirements and while direct DNA testing is an option, it's not always highly sensitive, and not all labs possess its capabilities.

[17] This likely leads to underreporting of M. hominis infections, causing delayed diagnosis and less favorable treatment outcomes[18] Cells of M. hominis prepared from batch cultures show uniform exponential growth and appear to divide through the process of binary fission with pleomorphic forms appearing upon further incubation.

[23] It prospers in the environment created by other gram negative bacteria implicated in bacterial vaginosis and may be a cause of preterm delivery and miscarriage.

M. hominis is also suspected to be the cause of neonatal infections such as conjunctivitis, respiratory distress, fever, meningitis, abscesses, and congenital pneumonia.

[23] Understanding how M. hominis contributes to infections in adult patients, particularly in areas outside the genital tract like the central nervous system (CNS), post-operative wound sites, the chest, and joints, has posed a challenge.

[24] Recent data shows an increase in reported post-operative CNS infections caused by Mycoplasma, likely due to the more extensive use of advanced diagnostic methods like PCR and DNA sequencing, especially when routine cultures fail to detect bacterial growth.

However, mycoplasma bacteria lack this cellular structure causing some antibiotics, like penicillin, to be ineffective treatment options.

[11] In locations and patient populations where tetracycline resistance or treatment failures are common, other drugs such as fluoroquinolones should be considered guided by in vitro susceptibility data when possible.

[11] In other cases such as severe M. hominis infections occurring in immunocompromised patients, combination of drugs usually active against the mycoplasmas have been recommended.